Kh. Z. Trapsh
Kh. Z. Trapsh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Алиса Зауровна Матуа
Institute of Experimental Pathology and Therapy, Academy of Sciences of Abkhazia
3 shared publications - Irina G. Kondzhariya
Institute of Experimental Pathology and Therapy, Academy of Sciences of Abkhazia
2 shared publications - Zurab Ya. Mikvabiya
Institute of Experimental Pathology and Therapy, Academy of Sciences of Abkhazia
2 shared publications З. Я. Миквабия
ГНУ «Институт экспериментальной патологии и терапии Академии наук Абхазии
2 shared publicationsA. G. Dyachenko
Sumy State University
1 shared publication- A.E. Nikonova
Federal Research Centre of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya, Ministry of Health of the Russian Federation, Moscow
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 28 (3) , 499-508
Cytokine response to bacterial translocation in a model of inflammatory bowel diseases in Macaca Mulatta monkeys
Inflammatory bowel diseases (IBD) comprise a heterogeneous group of disorders with various clinical and morphological manifestations representing significant issues in modern medicine. The aim of our study was to reproduce the signs of IBD in Macaca mulatta (Rhesus macaque) by oral administration of sodium dextran sulfate (DSS), and to assess the cytokine response to induced damage of intestinal barrier and translocation of bacterial components to the bloodstream. Mature Macaca mulatta males (n = 5), kept in the monkey breeding facility at the Research Institute of Experimental Pathology and Therapy were selected as the object of this study. Induction of inflammatory bowel disease in Rhesus macaque was carried out by oral administration of 5% sodium salt of sulfated dextran (DSS) (molecular weight of 40 000) at the volumes corresponding to physiological needs of animals. Immunological and molecular biology methods were used to determine cytokines and the microbial translocation markers. The results of the study showed that induction of IBD in Rhesus monkeys leads to a regular increase in the serum marker of 16S rDNA translocation from the 2nd day after DSS treatment, reaching maximum values on the sixth day. In parallel with increased bacterial translocation, we have revealed an increase in the cytokine response, i.e., a significant increase in the IL-6 and IFNγ concentrations. The stimulation of cytokine production in response to IBD induction was observed at the early stages, beginning from the 1st day, and reached its peak values on the 2nd to 6th days of exposure. It should be noted that the levels of inflammation markers remained high after the discontinuation of DSS, although they showed a gradual decrease towards the end of the experiment. Hence, a model of chemically induced inflammatory process in Macaca mulatta has been developed, characterized by a distinct, predominantly Th1cytokine profile, accompanied by pronounced microbial translocation. The duration of acute inflammation induced by DSS is comparable to the time required for transition into a chronic form. This model is a potentially valuable tool for further studying the pathogenesis and developing new treatments for IBD.
- 29 October 2026
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 28 (3) , 499-508
Open AccessCytokine response to bacterial translocation in a model of inflammatory bowel diseases in Macaca Mulatta monkeys
Inflammatory bowel diseases (IBD) comprise a heterogeneous group of disorders with various clinical and morphological manifestations representing significant issues in modern medicine. The aim of our study was to reproduce the signs of IBD in Macaca mulatta (Rhesus macaque) by oral administration of sodium dextran sulfate (DSS), and to assess the cytokine response to induced damage of intestinal barrier and translocation of bacterial components to the bloodstream. Mature Macaca mulatta males (n = 5), kept in the monkey breeding facility at the Research Institute of Experimental Pathology and Therapy were selected as the object of this study. Induction of inflammatory bowel disease in Rhesus macaque was carried out by oral administration of 5% sodium salt of sulfated dextran (DSS) (molecular weight of 40 000) at the volumes corresponding to physiological needs of animals. Immunological and molecular biology methods were used to determine cytokines and the microbial translocation markers. The results of the study showed that induction of IBD in Rhesus monkeys leads to a regular increase in the serum marker of 16S rDNA translocation from the 2nd day after DSS treatment, reaching maximum values on the sixth day. In parallel with increased bacterial translocation, we have revealed an increase in the cytokine response, i.e., a significant increase in the IL-6 and IFNγ concentrations. The stimulation of cytokine production in response to IBD induction was observed at the early stages, beginning from the 1st day, and reached its peak values on the 2nd to 6th days of exposure. It should be noted that the levels of inflammation markers remained high after the discontinuation of DSS, although they showed a gradual decrease towards the end of the experiment. Hence, a model of chemically induced inflammatory process in Macaca mulatta has been developed, characterized by a distinct, predominantly Th1cytokine profile, accompanied by pronounced microbial translocation. The duration of acute inflammation induced by DSS is comparable to the time required for transition into a chronic form. This model is a potentially valuable tool for further studying the pathogenesis and developing new treatments for IBD.
- Open Access
- 22 December 2024
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 24 (4) , 363-376
Safety, immunogenicity, and protective efficacy of the intranasal live pertussis vaccine GamLPV in an infant monkey model (Papio hamadryas)
INTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after vaccination with GamLPV, an intranasal recombinant live pertussis vaccine developed by the National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya. Further clinical development of GamLPV in paediatric volunteers, including infants, requires preclinical studies in a newborn monkey model.AIM. This study aimed to evaluate the safety, immunogenicity, and protective efficacy of the GamLPV vaccine in infant hamadryas baboons (Papio hamadryas) challenged with pertussis after intranasal vaccination.MATERIALS AND METHODS. The study used 20 hamadryas baboons, including 7 infants aged 1–1.5 months, 7 mothers of these infants, and 6 control animals. The study examined the time course of changes in serum levels of specific IgG antibodies to pertussis toxin (PT) and filamentous haemagglutinin (FHA) by enzyme-linked immunosorbent assay (ELISA), monitored changes in serum levels of Bordetella pertussis antibodies by agglutination immunoassay, and detected B. pertussis DNA in oropharyngeal aspirates by real-time polymerase chain reaction.RESULTS. Intranasal GamLPV administration to infant baboons induced the production of specific IgG antibodies to PT and FHA (ELISA) and an increase in the total pertussis antibody titre (agglutination immunoassay). GamLPV did not cause any injection site or systemic reactions. There were no changes in complete blood counts and serum biochemistry profiles after vaccination. The protective efficacy of GamLPV against B. pertussis was demonstrated in challenge tests, where immunised animals had no clinical signs or laboratory findings indicative of pertussis in contrast to controls.CONCLUSIONS. The study demonstrated the safety and immunogenicity of the intranasal live pertussis vaccine GamLPV in newborn hamadryas baboons. GamLPV shows promise in the primary vaccination of infants, the revaccination of children and adults, and the development of herd immunity against pertussis in families.
- 22 December 2024
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 24 (4) , 363-376
Open AccessSafety, immunogenicity, and protective efficacy of the intranasal live pertussis vaccine GamLPV in an infant monkey model (Papio hamadryas)
INTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after vaccination with GamLPV, an intranasal recombinant live pertussis vaccine developed by the National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya. Further clinical development of GamLPV in paediatric volunteers, including infants, requires preclinical studies in a newborn monkey model.AIM. This study aimed to evaluate the safety, immunogenicity, and protective efficacy of the GamLPV vaccine in infant hamadryas baboons (Papio hamadryas) challenged with pertussis after intranasal vaccination.MATERIALS AND METHODS. The study used 20 hamadryas baboons, including 7 infants aged 1–1.5 months, 7 mothers of these infants, and 6 control animals. The study examined the time course of changes in serum levels of specific IgG antibodies to pertussis toxin (PT) and filamentous haemagglutinin (FHA) by enzyme-linked immunosorbent assay (ELISA), monitored changes in serum levels of Bordetella pertussis antibodies by agglutination immunoassay, and detected B. pertussis DNA in oropharyngeal aspirates by real-time polymerase chain reaction.RESULTS. Intranasal GamLPV administration to infant baboons induced the production of specific IgG antibodies to PT and FHA (ELISA) and an increase in the total pertussis antibody titre (agglutination immunoassay). GamLPV did not cause any injection site or systemic reactions. There were no changes in complete blood counts and serum biochemistry profiles after vaccination. The protective efficacy of GamLPV against B. pertussis was demonstrated in challenge tests, where immunised animals had no clinical signs or laboratory findings indicative of pertussis in contrast to controls.CONCLUSIONS. The study demonstrated the safety and immunogenicity of the intranasal live pertussis vaccine GamLPV in newborn hamadryas baboons. GamLPV shows promise in the primary vaccination of infants, the revaccination of children and adults, and the development of herd immunity against pertussis in families.